| RG-6279 |
RG-6279 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
Solid tumours |
Details
|
| Anti-CTLA-4 and PD-1 CAR-T cell therapy (Shanghai Cell Therapy Research Institute) |
|
Phase 2 Clinical |
Shanghai Cell Therapy Research Institute |
Neoplasms |
Details
|
| RB-0004 |
RB-0004 |
Phase 1 Clinical |
Reyoung Pharmaceutical Co Ltd |
Solid tumours; Lymphoma |
Details
|
| 89Zr-N-sucDf-pembrolizumab |
|
Phase 1 Clinical |
Merck & Co Inc, Umcg The University Medical Center Groningen |
Carcinoma, Non-Small-Cell Lung; Melanoma |
Details
|
| PD-1 knockout EBV-CTL (Nanjing Medical University) |
|
Phase 2 Clinical |
Nanjing Medical University |
Stomach Neoplasms; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Nasopharyngeal Neoplasms; Lymphoma |
Details
|
| STW204 |
STW-204; AI025; AI-025 |
Phase 1 Clinical |
Suzhou Stainwei Biotech Inc |
Solid tumours; Neoplasms |
Details
|
| Recombinant humanized anti-PD-1 monoclonal antibody (Shanxi Wichida Bright Pharmaceutical) |
|
Phase 1 Clinical |
Shanxi Weiqidaguangming Pharmaceutical Co Ltd |
Solid tumours |
Details
|
| INSIX RA (Indus Biotech) |
|
Clinical |
Indus Biotech Pvt Ltd |
Arthritis, Rheumatoid; Inflammation |
Details
|
| Treprilimab |
|
Clinical |
Sun Yat-Sen University |
Oropharyngeal Neoplasms |
Details
|
| ABBV-1882 |
ABBV-1882 |
Phase 1 Clinical |
Abbvie Inc |
HIV Infections |
Details
|
| Pembrolizumab biosimilar (biocad) |
BCD-201 |
Phase 1 Clinical |
Biocad |
Solid tumours |
Details
|
| Anti-PD1/anti-TIM3 bispecific antibody (L&L vision biopharmaceuticals) |
Bis-5 |
Phase 1 Clinical |
|
Neoplasms |
Details
|
| Recombinant human anti-PD-1 monoclonal antibody(Cspc Pharmaceutical Technology ,Shijiazhuang) |
|
Phase 2 Clinical |
|
Carcinoma, Ovarian Epithelial; Bile Duct Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms |
Details
|
| SSGJ-706 |
SSGJ-706 |
Phase 1 Clinical |
Shanghai Cp Guojian Pharmaceutical Co Ltd |
Solid tumours; Lymphoma |
Details
|
| HerinCAR-PD1 |
|
Phase 2 Clinical |
Ningbo Cancer Hospital |
Solid tumours |
Details
|
| EBV-specific TCR-T cell with anti-PD1 auto-secreted element |
|
Phase 2 Clinical |
Tcrcure Biopharma Ltd |
Squamous Cell Carcinoma of Head and Neck |
Details
|
| Anti-CTLA-4/PD-1 expressing EGFR-CAR-T |
|
Phase 2 Clinical |
Shanghai Cell Therapy Research Institute |
Solid tumours |
Details
|
| CD19 PD-1/CD28 CAR-T Cell Therapy (Second Affiliated Hospital School Of Zhejiang University School Of Medicine) |
|
Phase 1 Clinical |
Second Affiliated Hospital Of Zhejiang University School Of Medicine |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma |
Details
|
| BCMA-PD1 CAR T cell therapy (General Hospital of the People's Liberation Army) |
|
Phase 2 Clinical |
People'S Liberation Army General Hospital Military Service |
Multiple Myeloma |
Details
|
| Recombinant human anti-PD-1 monoclonal antibody(Hec Biological) |
|
Phase 1 Clinical |
Dongguan City Hec Biological Medicine Res And Development Co Ltd |
Stomach Neoplasms; Esophageal adenocarcinoma |
Details
|
| dPD-1 hCD19 CART cell therapy (Innovative Cellular Therapeutics) |
ICTCAR-014 |
Phase 2 Clinical |
Innovative Cellular Therapeutics Co Ltd |
Lymphoma, Non-Hodgkin |
Details
|
| EGFRvIII-directed CAR-T cell tharapy (Novartis/University of Pennsylvania) |
LXF-821 |
Phase 1 Clinical |
University Of Pennsylvania, Novartis Pharma Ag |
Glioblastoma |
Details
|
| GNR-051 |
GNR-051 |
|
Generium Pharmaceuticals |
|
Details
|
| PF-07209960 |
PF-07209960 |
Phase 1 Clinical |
Pfizer Inc |
Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Carcinoma, Non-Small-Cell Lung |
Details
|
| CD-200-AR-L |
CD-200-AR-L; hP-1-A-8 |
Phase 1 Clinical |
University Of Minnesota |
Glioblastoma |
Details
|
| JS-201 |
JS-201 |
Phase 1 Clinical |
Shanghai Junshi Biosciences Co Ltd |
Neoplasms |
Details
|
| LBL-015 |
LBL-015 |
Phase 2 Clinical |
Nanjing Leads Biolabs Co Ltd |
Solid tumours |
Details
|
| SHR-1901 |
SHR-1901 |
Phase 1 Clinical |
Suzhou Suncadia Biopharmaceuticals Co Ltd |
Neoplasms |
Details
|
| SSI-361 |
LVGN-3616; SSI-361 |
Phase 2 Clinical |
Lyvgen Biopharma(HK)Ltd |
Neoplasms |
Details
|
| CA-170 |
CA-170; AUPM-170 |
|
Aurigene |
|
Details
|
| TQB-2868 |
TQB-2868 |
Phase 1 Clinical |
Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group |
Neoplasms |
Details
|
| Rosnilimab |
ANB-030 |
|
Anaptysbio Inc |
Alopecia Areata |
Details
|
| Peramprizumab |
|
Phase 2 Clinical |
Sun Yat-Sen University |
Nasopharyngeal Carcinoma |
Details
|
| Sym-024 |
Sym-024; S-95024 |
|
Symphogen A/S |
|
Details
|
| BI-1387446 |
|
|
C.H. Boehringer Sohn Ag & Co. Kg |
|
Details
|
| BCD-217 |
BCD-217 |
|
Biocad |
|
Details
|
| BAT-1308 |
BAT-1308 |
Phase 1 Clinical |
Bio-Thera Solutions Ltd |
Solid tumours |
Details
|
| CMAB-819 |
CMAB8-19 |
Phase 1 Clinical |
Sinomab Bioscience Ltd |
Squamous Cell Carcinoma of Head and Neck; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung |
Details
|
| Programmed cell death 1 antibody (Sun Yat-sen University) |
|
|
Sun Yat-Sen University |
|
Details
|
| Pegylated recombinant human granulocyte colony stimulating factor(Sun Yat-sen University) |
|
Phase 1 Clinical |
Sun Yat-Sen University |
Nasopharyngeal Carcinoma |
Details
|
| IAP-0971 |
IAP-0971 |
Phase 2 Clinical |
Shenghe (China) Biopharmaceutical Co Ltd |
Solid tumours; Neoplasms |
Details
|
| ZG-005 |
ZG-005 |
Phase 2 Clinical |
Suzhou Zelgen Biopharmaceuticals Co Ltd |
Solid tumours |
Details
|
| HX-009 |
HX-009 |
Phase 2 Clinical |
Hanx Biopharmaceutical Co Ltd, Wuhan Hanxiong Biotechnology Co Ltd |
Solid tumours; Liver Neoplasms; Stomach Neoplasms; Lymphoma |
Details
|
| Recombinant humanized anti-PD-1 monoclonal antibody (Anhui Anke Biotechnology) |
|
Phase 2 Clinical |
Anhui Anke Biotechnology (Group) Co Ltd |
Esophageal Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Lymphoma; Lung Neoplasms |
Details
|
| TY-101 |
TY-101; TY101 |
Phase 2 Clinical |
Tayu Huaxia Biotech Medical Group Co Ltd |
Solid tumours; Lymphoma |
Details
|
| MiHA-loaded PD-L silenced DC vaccination (Radboud University) |
|
Phase 2 Clinical |
Radboud University Nijmegen |
Hematologic Neoplasms; Colorectal Neoplasms |
Details
|
| CC-90006 |
C-90006; CC-90006 |
Phase 1 Clinical |
Anaptysbio Inc |
Autoimmune Diseases; Psoriasis |
Details
|
| SI-B003 |
SI-B003 |
Phase 1 Clinical |
Sichuan Baili Pharmaceutical Co Ltd |
Solid tumours; Stomach Neoplasms; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Neoplasm Metastasis; Melanoma |
Details
|
| Sym-021 |
Sym-021 |
Phase 1 Clinical |
Symphogen A/S |
Solid tumours; Lymphoma; Neoplasm Metastasis |
Details
|
| IMU-201 |
IMU-201 |
Phase 1 Clinical |
Imugene Ltd |
Adenocarcinoma of Lung; Carcinoma, Large Cell; Carcinoma, Squamous Cell; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| EBV-Specific TCR-T Cell therapy (Xinqiao Hospital of Chongqing) |
|
Phase 2 Clinical |
Xinqiao Hospital, Army Medical University |
Squamous Cell Carcinoma of Head and Neck |
Details
|
| Rituximab/Paclitaxel |
AR-160 |
Phase 1 Clinical |
Mayo Clinic |
Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
| Pimivalimab |
JTX-4014 |
Phase 2 Clinical |
Jounce Therapeutics Inc |
Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| AZD-2936 |
AZD-2936 |
Phase 2 Clinical |
Astrazeneca Plc |
Carcinoma, Non-Small-Cell Lung |
Details
|
| BA1104 |
LY-01015; BA-1104 |
Phase 1 Clinical |
Luye Pharma Group Ltd |
Liver Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Mesothelioma; Urinary Bladder Neoplasms; Glioma; Carcinoma, Non-Small-Cell Lung; Melanoma |
Details
|
| EMB-02 |
EMB-02 |
Phase 2 Clinical |
Shanghai Epimab Biotherapeutics, Inc |
Solid tumours; Neoplasms |
Details
|
| SSGJ-705 |
SSGJ-705 |
Phase 1 Clinical |
Shanghai Cp Guojian Pharmaceutical Co Ltd |
Solid tumours; Neoplasms |
Details
|
| Latikafusp |
AMG-256 |
Phase 1 Clinical |
Amgen Inc |
Solid tumours; Neoplasms |
Details
|
| RO-7121661 |
RG-7769; RO-7121661 |
Phase 2 Clinical |
F. Hoffmann-La Roche Ltd |
Solid tumours; Small Cell Lung Carcinoma; Neoplasms; Esophageal Squamous Cell Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung |
Details
|
| Lorigerlimab |
MGD-019; AEX1344 |
Phase 2 Clinical |
Macrogenics Inc |
Liver Neoplasms; Solid tumours; Skin Melanoma; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Neoplasms; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Neoplasm Metastasis; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung |
Details
|
| Recombinant human anti-PD-1 monoclonal antibody(Sumgen) |
SG-001; SYSA1802 |
Phase 2 Clinical |
Hangzhou Sumgen Biotechnology Co Ltd |
Solid tumours; Biliary Tract Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Ovarian Epithelial; Neoplasms; Mesothelioma; Cholangiocarcinoma; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Lymphoma; Gallbladder Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| ONCR-177 |
ONCR-177 |
Phase 1 Clinical |
Oncorus Inc |
Solid tumours; Liver Neoplasms; Squamous Cell Carcinoma of Head and Neck; Skin Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Melanoma |
Details
|
| Multiple target antigen stimulating cell therapy (HengRui YuanZheng Biotechnology) |
|
Phase 2 Clinical |
Hengrui Yuanzheng (Shanghai) Biotechnology Co Ltd |
Solid tumours; Liver Neoplasms; Stomach Neoplasms; Neoplasms; Liver Diseases |
Details
|
| Rulonilimab |
F-520 |
Phase 3 Clinical |
Shandong New Time Pharmaceutical Co Ltd |
Solid tumours; Lymphoma, T-Cell, Peripheral; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Transitional Cell; Neurolymphomatosis; Lymphoma; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms |
Details
|
| ONO-4685 |
ONO-4685 |
Phase 1 Clinical |
Merus Nv |
Psoriasis; Lymphoma, T-Cell |
Details
|
| IBI-363 |
IBI-363 |
Phase 1 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Solid tumours; Neoplasms; Lymphoma |
Details
|
| MK-3475A |
MK-3475A |
Phase 1 Clinical |
Merck Sharp & Dohme Corp |
Solid tumours |
Details
|
| Tebotelimab |
PD-1 X LAG-3; MGD-013 |
Phase 3 Clinical |
Macrogenics Inc |
Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Adenocarcinoma; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Endometrial Neoplasms; Cholangiocarcinoma; Small Cell Lung Carcinoma; Liver Neoplasms; Triple Negative Breast Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Biliary Tract Neoplasms; Ovarian Neoplasms; Hematologic Neoplasms; Head and Neck Neoplasms; Solid tumours |
Details
|
| Peresolimab |
LY-3462817 |
Phase 2 Clinical |
Eli Lilly And Company |
Autoimmune Diseases; Arthritis, Rheumatoid; Connective Tissue Diseases; Joint Diseases; Immune System Diseases; Psoriasis; Musculoskeletal Diseases; Rheumatic Diseases; Arthritis |
Details
|
| Finotonlimab |
SCT-I10A |
Phase 3 Clinical |
SinoCelltech Ltd |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Lymphoma; Esophageal Squamous Cell Carcinoma; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular |
Details
|
| Recombinant human PD-1 antibody herpes simplex virus |
|
Phase 1 Clinical |
Yangsheng Tang Co Ltd, Xiamen University |
Solid tumours; Liver Neoplasms; Head and Neck Neoplasms; Neoplasms; Pancreatic Neoplasms; Central Nervous System Neoplasms; Urinary Bladder Neoplasms; Colorectal Neoplasms; Brain metastases; Lung Neoplasms; Melanoma; Uterine Cervical Neoplasms |
Details
|
| Izuralimab |
XmAb-23104; XmAb-104 |
Phase 1 Clinical |
Xencor Inc |
Nasopharyngeal Carcinoma; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Endometrial Neoplasms; Colorectal Neoplasms; Sarcoma; Breast Neoplasms; Solid tumours; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms |
Details
|
| AK-129 |
AK-129 |
Phase 1 Clinical |
Zhongshan Akeso Biopharma Co Ltd |
Neoplasms |
Details
|
| MAX-10181 |
MAX-10181; MAX-1 |
Phase 1 Clinical |
Guangzhou Maxinovel Pharmaceiticals Co Ltd |
Solid tumours; Neoplasms |
Details
|
| Budigalimab |
ABBV-181 |
Phase 2 Clinical |
Abbvie Inc |
Solid tumours; HIV Infections; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| QL1604 |
QL1604; QL-1604 |
Phase 3 Clinical |
Qilu Pharmaceutical Co Ltd |
Liver Neoplasms; Solid tumours; Neoplasms; Uterine Cervical Neoplasms; Adenocarcinoma; Carcinoma, Hepatocellular |
Details
|
| Taminadenant |
NIR-178; PBF-509 |
Phase 2 Clinical |
Palobiofarma Sl |
Head and Neck Neoplasms; Solid tumours; Ovarian Neoplasms; Carcinoma, Renal Cell; Carcinoma; Triple Negative Breast Neoplasms; Lymphoma, Large B-Cell, Diffuse; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Colorectal Neoplasms; Parkinson Disease; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Melanoma |
Details
|
| PE0105 |
PE-0105 |
Phase 1 Clinical |
Shanghai Yunyi Health Technology Development Co Ltd |
Neoplasms |
Details
|
| MEDI-5752 |
MEDI-5752 |
Phase 1 Clinical |
Medimmune Llc |
Solid tumours; Carcinoma, Renal Cell |
Details
|
| RO-7247669 |
RO-7247669 |
Phase 2 Clinical |
F. Hoffmann-La Roche Ltd |
Solid tumours; Liver Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Esophageal Squamous Cell Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung |
Details
|
| T3011 |
MVR-T3011; T3011; MVR-T3011 IT; MVR-T3011 IV |
Phase 2 Clinical |
Immvira Co Ltd |
Breast Neoplasms; Carcinoma, Hepatocellular; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Endometrial Neoplasms; Lymphoma; Lung Neoplasms; Colorectal Neoplasms; Solid tumours; Sarcoma; Mesothelioma; Skin Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Head and Neck Neoplasms; Ovarian Neoplasms; Liver Neoplasms |
Details
|
| PD-1 knockout engineered T cells (Chengdu MedGenCell) |
|
Phase 2 Clinical |
West China Hospital Of Sichuan University, Chengdu Medgencell |
Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma |
Details
|
| Pembrolizumab/Quavonlimab |
MK-1308A |
Phase 3 Clinical |
Merck Sharp & Dohme Corp, Msd Ireland (Carlow), Moshadong R & D (China) Co Ltd |
Solid tumours; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Colorectal Neoplasms; Carcinoma, Hepatocellular; Melanoma |
Details
|
| PD-1 knockout engineered T cells (Anhui Kedgene Biotechnology) |
|
Phase 2 Clinical |
Anhui Korton Biological Technology Co Ltd, Hangzhou Cancer Hospital |
Esophageal Neoplasms |
Details
|
| Zeluvalimab |
AMG-404 |
Phase 2 Clinical |
Amgen Inc |
Solid tumours; Small Cell Lung Carcinoma; Neoplasms; Prostatic Neoplasms, Castration-Resistant; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
| Vudalimab |
XmAb-20717; XmAb-717 |
Phase 2 Clinical |
Xencor Inc |
Carcinoma, Neuroendocrine; Vulvar Neoplasms; Prostatic Neoplasms; Cholangiocarcinoma; Adenocarcinoma, Clear Cell; Colorectal Neoplasms; Astrocytoma; Carcinoma, Squamous Cell; Thymoma; Breast Neoplasms; Fallopian Tube Neoplasms; Endometrial Neoplasms; Thyroid Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Biliary Tract Neoplasms; Nasopharyngeal Carcinoma; Prostatic Neoplasms, Castration-Resistant; Adnexal Diseases; Mesothelioma; Adenoma, Acidophil; Carcinoma, Ovarian Epithelial; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Basal Cell; Ovarian Neoplasms; Solid tumours |
Details
|
| Mavezelimab/Pembrolizumab |
MK-4280A; MK-4820A |
Phase 3 Clinical |
Msd Ireland (Carlow) Merck Sharp & Dohme Corp, Moshadong R & D (China) Co Ltd |
Solid tumours; Carcinoma, Renal Cell; Hodgkin Disease; Small Cell Lung Carcinoma; Colorectal Neoplasms |
Details
|
| Iparomlimab/Tuvonralimab |
QL-1706; PSB-205; PBS-103/PBS-105 |
Phase 3 Clinical |
Qilu Pharmaceutical Co Ltd |
Liver Neoplasms; Solid tumours; Carcinoma, Renal Cell; Neoplasms; Small Cell Lung Carcinoma; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| Spartalizumab |
PDR-001 |
Phase 3 Clinical |
Novartis Pharma Ag |
Carcinoma, Pancreatic Ductal; Chordoma; Urinary Bladder Neoplasms; Uveal melanoma; Nasopharyngeal Carcinoma; Prostatic Neoplasms; Breast Neoplasms; Sarcoma; Cholangiocarcinoma; Colorectal Neoplasms; Primary Myelofibrosis; Gastrointestinal Stromal Tumors; Bone Marrow Diseases; Endometrial Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Squamous Cell; Prostatic Neoplasms, Castration-Resistant; Lung Neoplasms; Lymphoma; Sarcoma, Alveolar Soft Part; Leukemia, Myeloid, Acute; Esophageal adenocarcinoma; Uterine Neoplasms; Metastatic breast cancer; Thyroid Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Adenocarcinoma; Persistent Fetal Circulation Syndrome; Carcinoma, Endometrioid; Triple Negative Breast Neoplasms; Ovarian Neoplasms; Liver Neoplasms; Leukemia, Myeloid; Leukemia; Head and Neck Neoplasms; Kidney Neoplasms; Preleukemia; Hematologic Diseases; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Carcinoma; Stomach Neoplasms |
Details
|
| TC-510 |
TC-510 |
Phase 2 Clinical |
Tcr2 Therapeutics Inc |
Solid tumours; Ovarian Neoplasms; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Mesothelioma; Colorectal Neoplasms; Adenocarcinoma |
Details
|
| Pembrolizumab/Vibostolimab |
MK-7684A |
Phase 3 Clinical |
Merck & Co Inc |
Ovarian Neoplasms; Hematologic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Neoplasms; Urinary Bladder Neoplasms; Cholangiocarcinoma; Endometrial Neoplasms; Gallbladder Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms |
Details
|
| Ezabenlimab |
BI-754091 |
Phase 2 Clinical |
C.H. Boehringer Sohn Ag & Co. Kg |
Head and Neck Neoplasms; Solid tumours; Rectal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Pancreatic Neoplasms; Neoplasms; Colonic Neoplasms; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Squamous Cell; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Melanoma |
Details
|
| Carrelizumab |
|
Phase 3 Clinical |
Beijing Chest Hospital |
Stomach Neoplasms; Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| Sasanlimab |
PF-06801591; PF-6801591; RN-888 |
Phase 3 Clinical |
Pfizer Pharmaceuticals Ltd (China) |
Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Endometrial Neoplasms; Carcinoma, Squamous Cell; Colorectal Neoplasms; Bile Duct Neoplasms; Prostatic Neoplasms; Sarcoma; Urinary Bladder Neoplasms; Carcinoma, Transitional Cell; Solid tumours; Pancreatic Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma; Carcinoma, Renal Cell; Liver Neoplasms; Head and Neck Neoplasms; Ovarian Neoplasms |
Details
|
| Cetrelimab |
JNJ-63723283; JNJ-3283 |
Phase 3 Clinical |
Johnson & Johnson |
Hepatitis B, Chronic; Neoplasms; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Multiple Myeloma; Prostatic Neoplasms; Carcinoma, Neuroendocrine; Carcinoma, Small Cell |
Details
|
| Retifanlimab |
INCMGA-0012; INCMGA-00012; MGA-012 |
Phase 3 Clinical |
Macrogenics Inc |
Esophageal adenocarcinoma; Prostatic Neoplasms; Sarcoma; Lymphoma, Follicular; Breast Neoplasms; Astrocytoma; Colorectal Neoplasms; Glioma; Endometrial Neoplasms; Carcinoma, Pancreatic Ductal; Urinary Bladder Neoplasms; Carcinoma, Squamous Cell; Penile Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Endometrioid; Melanoma; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms; Anus Neoplasms; Head and Neck Neoplasms; Lymphoma, B-Cell; Ovarian Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Carcinoma, Merkel Cell; Solid tumours; Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Lymphoma, Large B-Cell, Diffuse; Glioblastoma; Oligodendroglioma; Liposarcoma |
Details
|
| CD19-PD1-CAR T cell therapy (Chinese PLA General Hospital) |
|
Phase 2 Clinical |
Pla General Hospital |
Lymphoma, B-Cell |
Details
|
| INCA-32459 |
INCA-32459 |
Phase 1 Clinical |
Incyte Corp, Merus Nv |
Neoplasms |
Details
|
| Ivonescimab |
AK-112 |
Phase 3 Clinical |
Zhongshan Akeso Biopharma Co Ltd |
Ovarian Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Breast Neoplasms; Colorectal Neoplasms; Genital Neoplasms, Female; Endometrial Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular |
Details
|
| LZM-009 |
LZM-009 |
Phase 2 Clinical |
Livzon(Group) Pharmaceutical Factory |
Solid tumours; Thymoma; Carcinoma, Non-Small-Cell Lung |
Details
|
| MW-11 |
MW-11; 9MW1111; 9-MW1111; 9MW-1111; 9-MW-1111 |
Phase 1 Clinical |
Mabwell (Shanghai) Bioscience Co Ltd |
Solid tumours; Breast Neoplasms |
Details
|
| Acrixolimab |
YBL-006; YBL 006 |
Phase 2 Clinical |
Y-biologics Inc |
Solid tumours; Neoplasms |
Details
|
| IBI-319 |
IBI-319 |
Phase 1 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Neoplasms |
Details
|
| IBI-321 |
IBI-321 |
Phase 1 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Solid tumours; Neoplasms |
Details
|
| PH-762 |
PH-762 |
Phase 1 Clinical |
Phio Pharmaceuticals Corp |
Breast Neoplasms; Melanoma |
Details
|
| Pidilizumab |
MDV-9300; CT-011 |
Phase 2 Clinical |
Curetech Ltd |
Ovarian Neoplasms; Carcinoma, Renal Cell; Lymphoma, Large B-Cell, Diffuse; Pancreatic Neoplasms; Colonic Neoplasms; Multiple Myeloma; Prostatic Neoplasms; Sarcoma; Breast Neoplasms; Colorectal Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Melanoma; Carcinoma, Hepatocellular; Hepatitis C, Chronic |
Details
|
| Reozalimab |
IBI-318; LY-3434172; LY3434172 |
Phase 2 Clinical |
Innovent Biologics(Suzhou) Co Ltd, Eli Lilly And Company |
Neoplasms; Small Cell Lung Carcinoma; Lymphoma, Extranodal NK-T-Cell; Carcinoma, Squamous Cell; Carcinoma, Hepatocellular |
Details
|
| Fidasimtamab |
IBI-315 |
Phase 1 Clinical |
Hanmi Pharmaceutical Co Ltd, Innovent Biologics(Suzhou) Co Ltd |
Solid tumours; Neoplasms |
Details
|
| Nofazinlimab |
CS-1003 |
Phase 3 Clinical |
Cstone Pharmaceuticals |
Solid tumours; Neoplasms; Lymphoma; Carcinoma, Hepatocellular |
Details
|
| Recombinant humanized anti-PD-1 monoclonal antibody (Shanghai CP Guojian) |
609-A; SSGJ-609A; SSGJ-609-A |
Phase 2 Clinical |
Shanghai Cp Guojian Pharmaceutical Co Ltd |
Solid tumours; Sarcoma; Breast Neoplasms |
Details
|
| AZD-7789 |
AZD-7789 |
Phase 2 Clinical |
AstraZeneca Ag |
Hodgkin Disease; Carcinoma, Non-Small-Cell Lung |
Details
|
A-Z
